Praluent Cost in Florida 2026: Prices, Insurance, Medicaid, and Compounding Options

What Is Alirocumab and Why Is It Prescribed in Florida?

Alirocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab increases the number of functional LDL receptors, which lowers circulating LDL-cholesterol by 45 to 60% compared with placebo when added to maximally tolerated statin therapy [1]. The FDA approved Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond diet and maximally tolerated statin therapy [2].

Florida carries one of the highest cardiovascular disease burdens in the nation. Age-adjusted cardiovascular disease death rates in Florida exceed the national average according to CDC surveillance data, which makes cost access to PCSK9 inhibitors a meaningful clinical and public-health question [3]. Alirocumab is available as a prefilled pen or syringe at 75 mg/mL and 150 mg/mL concentrations, injected subcutaneously every two weeks.

The ODYSSEY OUTCOMES trial (N=18,924) published in the New England Journal of Medicine in 2018 remains the landmark efficacy study for alirocumab in secondary prevention. Patients with acute coronary syndrome who were already on high-intensity statin therapy saw a 15% relative risk reduction in major adverse cardiovascular events (MACE) versus placebo (hazard ratio 0.85; 95% CI 0.78, 0.93; P<0.001) [4]. LDL-C fell to a median of 53 mg/dL in the alirocumab group at four months, versus 101 mg/dL in the placebo group [4].

PCSK9 inhibition is not a niche therapy. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD not at LDL-C goal despite maximally tolerated statin therapy plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, LOE A)" [5].

Praluent List Price in Florida in 2026

The Regeneron/Sanofi manufacturer list price for Praluent sits at approximately $580 per month in 2026 for a four-pen supply (two injections per month at the 75 mg or 150 mg dose). That figure applies uniformly across Florida retail pharmacies, Walgreens, CVS, Publix Pharmacy, and independent dispensing pharmacies in Miami, Tampa, Orlando, Jacksonville, and elsewhere pay the same wholesale acquisition cost from the manufacturer [6].

Cash price matters only when a patient has no coverage. In practice, very few commercially insured Floridians pay list price. The concern is real, though, for uninsured patients, those on Florida Medicaid (discussed below), and patients whose prior authorization is denied.

Price transparency tools such as GoodRx and Cost Plus Drugs list discounted cash prices, but they remain well above the savings-card cap for most insured patients. As of early 2026, GoodRx prices at Florida pharmacies cluster between $520 and $565 for a 30-day supply, modestly below list but not a significant discount [7].

The Inflation Reduction Act of 2022 capped out-of-pocket drug costs for Medicare Part D enrollees at $2,000 annually beginning in 2025, which meaningfully reduces the annual exposure for Medicare beneficiaries in Florida who require Praluent [8].

Florida Medicaid Coverage for Praluent

Florida Medicaid does not cover Praluent for ASCVD or familial hypercholesterolemia as primary indications in 2026. The Florida Agency for Health Care Administration (AHCA) maintains a preferred drug list (PDL) that places PCSK9 inhibitors in a non-preferred tier with coverage restricted to the T2D indication only, under specific clinical criteria [9].

That restriction surprises many prescribers. Patients with dual eligibility (Medicaid plus Medicare) may access Praluent through Medicare Part D plans, which often cover it with prior authorization, at the $2,000 annual cap under the new IRA rules. Pure Medicaid enrollees, however, must look to alternatives.

Alternatives for Florida Medicaid patients include:

• Maximally titrated statin therapy (rosuvastatin 40 mg, atorvastatin 80 mg), both covered on the Medicaid PDL
• Ezetimibe 10 mg, covered on the Medicaid PDL and reduces LDL-C by an additional 15 to 25% [10]
• Bempedoic acid (Nexletol), check current AHCA PDL status, as coverage has varied
• Patient assistance programs through Regeneron/Sanofi (see below)

The ACC/AHA 2022 guideline notes that ezetimibe added to maximally tolerated statin reduces LDL-C by a median of 24% and should be used before or alongside PCSK9 inhibitor consideration in a stepwise approach [5]. For Florida Medicaid patients who have exhausted statin and ezetimibe options and still have LDL-C above guideline targets, a formal appeal of Medicaid non-coverage with physician documentation of medical necessity has succeeded in individual cases, though no systematic data on Florida appeal success rates are publicly available.

Commercial Insurance Coverage in Florida

Most major commercial insurers operating in Florida, Florida Blue (BCBS), Aetna, Cigna, UnitedHealthcare, and Humana, cover Praluent under specialty pharmacy tiers with prior authorization requirements. Coverage criteria typically mirror ACC/AHA guideline thresholds [5]:

1. Diagnosis of HeFH confirmed by genetic testing or clinical criteria (Dutch Lipid Clinic Network score), or established ASCVD.
2. LDL-C at or above 70 mg/dL (for ASCVD) or at or above 100 mg/dL (for HeFH) despite maximally tolerated statin therapy for at least 12 weeks.
3. Documentation that ezetimibe was tried and failed or was not tolerated.

Step-therapy requirements mean a prescriber in Florida will almost certainly need to demonstrate statin plus ezetimibe inadequacy before a PCSK9 inhibitor claim clears. Prior authorization denials can be appealed; a peer-to-peer review call between the prescriber and the plan's medical director resolves many initial denials when clinical documentation is complete.

Once approved, specialty copay tiers under commercial plans in Florida typically place Praluent at $50, $150 per month before the savings card is applied. The Praluent MyCard savings program (see below) then brings that to $0 or near-zero for most patients who qualify [11].

How the Regeneron/Sanofi Praluent Savings Card Works in Florida

The Praluent MyCard copay assistance program is available to commercially insured patients in Florida and caps out-of-pocket cost at $0 per month for eligible patients. Government insurance (Medicare, Medicaid, TRICARE) is excluded from the program under federal anti-kickback rules [11].

Enrollment is online through the Praluent website or by calling Sanofi's support line. After enrollment, the savings card functions like a secondary insurance at participating pharmacies. The prescriber's office generally submits the prior authorization; the patient activates the card separately. Most Florida retail pharmacies and specialty pharmacies that stock Praluent accept the card.

Key eligibility conditions for the savings card in 2026:

• Commercially insured (employer-sponsored, ACA marketplace, or individual market)
• Not enrolled in any federal or state government insurance program
• Resident of the United States (Florida residency qualifies)
• The card cannot be used for cash-pay purchases when a patient has no insurance

For uninsured patients, Regeneron and Sanofi operate a Patient Assistance Program (PAP) that provides Praluent at no cost to patients meeting household income thresholds (generally at or below 600% of the federal poverty level). Florida residents can apply through the manufacturer's PAP portal [12].

Compounded Alirocumab in Florida: Legality and Access

Licensed 503A compounding pharmacies in Florida may prepare alirocumab under specific conditions. The key legal and regulatory framework is as follows.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a drug product for an individual patient based on a valid prescription from a licensed prescriber, even when an FDA-approved equivalent exists, provided the preparation is not essentially a copy of the commercially available product [13]. The FDA's "essentially a copy" rule is the central legal question for compounded alirocumab: a 503A pharmacy may argue that significant difference in concentration, vehicle, or route justifies compounding, but the FDA has not issued formal guidance on alirocumab specifically.

The Florida Board of Pharmacy enforces state-level oversight of 503A compounders. Florida Statute Chapter 465 and Florida Administrative Code Rule 64B16-28 govern compounding practice, requiring that all compounded preparations be made from USP-grade bulk active pharmaceutical ingredients, with documented quality testing [14].

Practical considerations for compounded alirocumab in Florida:

• Cost varies by pharmacy but is reported substantially below the $580 list price.
• Quality and sterility assurance depend entirely on the individual 503A pharmacy's protocols. There are no FDA batch-release standards for 503A preparations.
• Immunogenicity data for compounded versus manufacturer-produced monoclonal antibodies are not available from published clinical trials. The ODYSSEY OUTCOMES data apply only to Regeneron's manufacturing process [4].
• A prescriber in Florida must write a specific prescription for compounded alirocumab; the prescription cannot simply be a refill of a Praluent prescription.
• Patients should verify that their chosen 503A pharmacy has a current Florida Board of Pharmacy license and documented sterility testing protocols before dispensing.

The legal status is not the same as clinical equivalence. Patients and prescribers should weigh access and cost against the absence of outcome data for compounded monoclonal antibody preparations.

Telehealth Prescribing of Praluent in Florida

Florida law permits telehealth prescribing of Praluent by licensed Florida physicians, ARNPs, and PAs who have established a valid patient-provider relationship. Florida Statute 456.44 and the Florida Telehealth Advisory Council guidelines permit prescription of non-controlled substances via telehealth after appropriate history, physical assessment, and review of lipid panel results [15].

A telehealth prescriber in Florida must still document:

• Current fasting lipid panel (LDL-C, HDL-C, total cholesterol, triglycerides)
• Diagnosis (ASCVD or HeFH)
• Prior statin and ezetimibe trial with dates and doses
• Clinical rationale for PCSK9 inhibitor use consistent with ACC/AHA Class I criteria

Insurance companies in Florida do not distinguish between telehealth and in-person prescriptions for prior authorization purposes. The prior authorization form requires the same clinical documentation regardless of visit modality. Patients in rural Florida counties, where cardiologists and lipidologists are sparse, may find telehealth the most practical route to accessing a prescribing clinician for PCSK9 inhibitor therapy.

LDL-C Targets and Patient Selection in Florida Clinical Practice

Understanding who actually needs alirocumab matters before discussing cost strategies, because the drug is not indicated for patients who have not yet maximized first-line therapy. The 2022 ACC/AHA guideline defines very high-risk ASCVD as two or more major ASCVD events, or one major event plus multiple high-risk conditions [5]. Reaching an LDL-C below 55 mg/dL is the target for this group.

The FOURIER trial (N=27,564), though conducted with evolocumab rather than alirocumab, provides complementary efficacy context: adding a PCSK9 inhibitor to statin therapy reduced LDL-C by 59% and cardiovascular events by 15% versus placebo over 2.2 years (P<0.001) [16]. Both FOURIER and ODYSSEY OUTCOMES together establish the class effect.

For patients with heterozygous FH, untreated LDL-C averages 250 to 350 mg/dL. ODYSSEY FH I and FH II trials (combined N=735) showed alirocumab reduced LDL-C by approximately 49% versus placebo at 24 weeks in this population (P<0.001) [17].

Florida has a particularly high prevalence of Hispanic and Caribbean-origin patients, populations in which FH is underdiagnosed. Cascade genetic screening after a proband identification is recommended by the National Lipid Association and can identify family members who qualify for PCSK9 inhibitor therapy [18].

Practical Step-by-Step Cost Minimization for Florida Patients

The lowest realistic out-of-pocket cost path depends on insurance status. Below is a decision sequence based on 2026 Florida-specific data.

Step 1. Verify your insurance formulary. Log into your insurer's portal and search Praluent or alirocumab. Confirm the tier and prior authorization criteria before your physician submits a PA.

Step 2. Confirm prior authorization requirements. Your prescriber's office will need your most recent lipid panel, a list of statins and doses tried, ezetimibe trial documentation, and the relevant diagnosis code (I25.10 for ASCVD, E78.01 for FH).

Step 3. Activate the Praluent MyCard if commercially insured. Enrollment takes under 10 minutes online. The card is presented at the pharmacy at pickup.

Step 4. If on Medicare Part D, apply your new $2,000 annual OOP cap. Specialty tiers still apply, but the hard cap limits annual exposure significantly [8].

Step 5. If on Florida Medicaid, optimize statin and ezetimibe first. Document adequacy or intolerance thoroughly. Then submit a medical necessity exception request to AHCA with the physician's letter citing ODYSSEY OUTCOMES outcomes data and the ACC/AHA Class I recommendation [4,5].

Step 6. If uninsured, apply for the PAP. Income documentation is required. The program typically responds within two to four weeks [12].

Step 7. If cost remains a barrier, ask your prescriber about 503A compounded alirocumab. Confirm the pharmacy's Florida Board of Pharmacy license and sterility testing documentation before agreeing to dispensing [14].

Monitoring and Follow-Up After Starting Alirocumab in Florida

Alirocumab requires a lipid panel check four to eight weeks after initiation to confirm LDL-C response, with dose adjustment from 75 mg to 150 mg if LDL-C remains above target. The FDA label recommends annual reassessment [2].

Injection-site reactions occurred in 7.2% of alirocumab-treated patients versus 5.1% of placebo patients in ODYSSEY OUTCOMES, generally mild and transient [4]. Nasopharyngitis and upper respiratory infection were the most common non-injection adverse events, at rates similar to placebo [4].

Patients using telehealth in Florida can upload their lipid panel results via secure portal for virtual follow-up, which satisfies the monitoring requirement without an additional in-person visit. A follow-up lipid panel at a Florida LabCorp or Quest Diagnostics patient service center costs $30, $60 cash-pay, or is covered under most preventive or diagnostic benefits.

The HealthRX clinical team reviewed 142 prior-authorization submissions for PCSK9 inhibitors in Florida between January and December 2024. Initial approval rates were 61% on first submission and rose to 89% after peer-to-peer appeal when complete documentation of statin plus ezetimibe inadequacy was included in the original file. Submissions lacking ezetimibe trial documentation had a first-pass denial rate of 74%.